
    
      The primary goal of the study is to analyze anti-telomerase specific memory responses in
      blood of long term survival patients and to correlate these immune responses to their
      subsequent treatment since the end of INVAC1-CT-101 phase I study. Six patients are expected
      to participate in this study.
    
  